|
Forest’s Newly Approved COPD Treatment Joins Crowded Market
The FDA Monday approved Forest Laboratories and Almirall’s Tudorza Pressair for the treatment of bronchospasm related to chronic obstructive pulmonary disease, adding another treatment to an already crowded U.S. chronic obstructive pulmonary disease (COPD) market.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives